We can’t show the full text here under this license.
Heart and Kidney Results of GLP-1 Receptor Agonist Treatment in Type 2 Diabetes with Chronic Kidney Disease
Updated
Abstract
In a study of 18,042 patients, GLP-1 receptor agonists were associated with a lower rate of compared to placebo.
- Treatment with GLP-1 receptor agonists resulted in a risk ratio of 0.82 for major adverse kidney events, indicating a significant reduction.
- A slightly lower incidence of all-cause mortality was observed, with a hazard ratio of 0.84, although this finding has moderate certainty.
- The protective effect on kidney events was consistent in patients with stage 3b , showing a risk ratio of 0.78.
- No significant differences were found in major adverse cardiovascular events or cardiovascular mortality, which may be due to insufficient statistical power.
Simplified
Key numbers
0.82
Reduction in
Risk ratio for with GLP-1 RAs vs. placebo.
0.84
Lower All-Cause Mortality Rate
for all-cause mortality with GLP-1 RAs vs. placebo.
18,042
Sample Size
Total number of patients included in the meta-analysis.